Update on antiplatelet therapy for stroke prevention.

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Ischemic stroke leads to high mortality and disability rates, necessitating effective preventive strategies.
• Patients with transient ischemic attack (TIA) or stroke face a high risk of recurrence.
• Risk-factor management is crucial for individuals with cerebrovascular disease.

Purpose of the Study:

• To evaluate the efficacy and safety of antiplatelet therapies for secondary stroke prevention.
• To assess the combination of low-dose aspirin plus extended-release dipyridamole compared to monotherapy.

Main Methods:

• The study involved analyzing data from the second European Stroke Prevention Study.
• Participants included patients who had experienced a transient ischemic attack or stroke.
• Treatment groups received aspirin, ticlopidine, clopidogrel, or a combination of aspirin and extended-release dipyridamole.

Main Results:

• The combination of low-dose aspirin plus extended-release dipyridamole was significantly more effective than aspirin alone in preventing recurrent stroke.
• This combination demonstrated a favorable safety profile with few treatment-related adverse effects.
• The combination therapy proved superior to monotherapy in the studied patient population.

Conclusions:

• Low-dose aspirin plus extended-release dipyridamole is a safe and effective first-line treatment for stroke prevention in high-risk patients.
• This combination therapy represents a significant advancement in secondary stroke prevention strategies.
• The findings support current recommendations for using this combination after TIA or stroke.